We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

DiaSorin to Acquire Siemens' ELISA Immunodiagnostics Business

By LabMedica International staff writers
Posted on 01 Aug 2017
Print article
DiaSorin S.p.A. (Saluggia, Italy) has entered into an agreement to acquire Siemens Healthineers’ (Erlangen, Germany) micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.

DiaSorin develops, produces and markets reagent kits for IVD worldwide, and offers a broad range of specialty tests in the immunodiagnostics market and new tests in the molecular diagnostics markets. Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company’s ELISA immunodiagnostic products are marketed in hospitals, private laboratories and blood banks.

DiaSorin will acquire the ELISA immunodiagnostic business portfolio and relevant assets from Siemens Healthineers, excluding the transfer of employees or manufacturing facility and capability, on a debt-free cash-free basis for a total consideration of up to Euro 47.5 million.

Siemens Healthineers will continue to manufacture and provide its ELISA immunodiagnostic reagent kits exclusively to DiaSorin for up to three years, enabling continuous supply of its current ELISA immunodiagnostic products to customers.

The acquisition is in line with DiaSorin’s strategy to convert customers using ELISA products to its CLIA platforms and products solution, leveraging on the completeness of its CLIA menu and the features of its LIAISON platforms. Siemens Healthineers’ ELISA immunodiagnostic business portfolio will allow DiaSorin to access a significant customer base, mostly in Europe, thus providing it with the opportunity to further expand its global commercial presence to create new business opportunities for the promotion and marketing of its CLIA products.

“We are very excited to acquire the Siemens Healthineers ELISA business,” said Carlo Rosa, CEO of DiaSorin Group. “We think this deal would perfectly fit with our long-term strategy aimed at expanding our customer base leveraging on our extensive CLIA specialties menu and LIAISON Platforms.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.